Kidney disease

Kidneys
#BioMed X #Diabetes #European Union #Kidney disease

Global research launched into early diabetic kidney disease 

Pharma innovation hub BioMed X has partnered with the government of Barbados to launch global research into a therapy for early diabetic kidney disease.  The new global call for research proposals, entitled ‘AI-Enabled Therapy of Early Diabetic Kidney Disease in Barbados’, addresses the biological heterogeneity of early diabetic kidney disease in… Read More

#Business & Investment #News

#Antisense Oligonucleotides (ASOs) #CAMP4 Therapeutics #Collaboration #GSK #Kidney disease #Neurodegenerative disorders

CAMP4 and GSK advance RNA-based therapeutic discoveries

GSK and CAMP4 Therapeutics have entered into a strategic research, collaboration and license agreement to identify and develop antisense oligonucleotide (ASO) drug candidates for multiple gene targets relevant to neurodegenerative and kidney disease indications.  “Protein under-expression plays a critical role in diseases such as neurodegenerative and kidney… Read More

#Business & Investment #News

Human kidneys
#Kidney disease #MHRA #Nephrology #Phase I trial #Purespring Therapeutics

UK approval for Purespring’s precision nephrology trial

Purespring Therapeutics’ UK Clinical Trial Application (CTA) for a planned Phase I/II study of PS-002 in patients with IgA nephropathy (IgAN) has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA), the NHS Health Research Authority (HRA) and Research Ethics Committee (REC).  PS-002… Read More

#News #Regulatory

Kidneys
#AstraZeneca #Chronic kidney disease (CKD) #Kidney disease #National Institute for Health and Care Excellence (NICE)

More patients to become eligible for chronic kidney disease treatment 

The UK National Institute for Health and Care Excellence (NICE) has published updated Final Draft Guidance recommending AstraZeneca’s Forxiga (dapagliflozin) as an option to treat chronic kidney disease (CKD) in adults in certain cases. This is the case if: It is an add-on to optimised standard care including the highest… Read More

#News

#Kidney disease #Mergers and acquisitions #microRNAs #Novartis

Novartis acquires investigational microRNA inhibitor

Novartis has entered into an agreement to acquire Regulus Therapeutics, a clinical-stage biopharmaceutical company focused on developing microRNA therapeutics.  Regulus’ lead asset, farabursen, is a next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD).  “With limited treatment options currently available… Read More

#Business & Investment #News

#European Medicines Agency #Gene therapy #Kidney disease #Orphan drugs #Purespring Therapeutics

EMA orphan designation for IgA nephropathy gene therapy

The European Medicines Agency (EMA) has granted orphan drug designation to Purespring Therapeutics’ PS-002 in IgA nephropathy (IgAN), an autoimmune kidney disease that primarily affects young adults.  Orphan drug designation in the European Union (EU) provides incentives including market exclusivity, protocol assistance (guidance on study design and… Read More

#News #Regulatory

Human kidneys
#Autoimmune disease #Everest Medicines #Kidney disease #Phase I trial

Positive results for BTK inhibitor for primary membranous nephropathy

Everest Medicines has revealed positive results in the ongoing Phase Ib/IIa clinical trial for the treatment of primary membranous nephropathy (pMN) with EVER001 (previously known as XNW1011).  In an analysis of the data, results from the trial showed that for patients in the low-dose cohort who have… Read More

#News

Kidneys
#Clinical trial #Kidney disease #Nephrology #Takeda #Vera Therapeutics

Positive news for IgAN treatment presented at Kidney Week

Positive data from two trials in immunoglobulin A nephropathy (IgAN) were shared at the American Society of Nephrology Kidney Week 2024 in San Diego, California. Vera Therapeutics announced data from its ORIGIN Phase IIb trial of atacicept that showed stabilised kidney function through 96 weeks of… Read More

#News #Trending News

Kidneys
#Financing #Gene therapy #Kidney disease #Purespring Therapeutics

Financing to transform the treatment of kidney diseases

Purespring Therapeutics, a gene therapy company focused on the treatment of kidney diseases, has raised £80 ($105) million in Series B financing. The oversubscribed round was led by Sofinnova Partners, in collaboration with Gilde Healthcare, Forbion, British Patient Capital and founding investor Syncona. Read More

#News

Kidneys
#Boehringer Ingelheim #Chronic kidney disease (CKD) #Kidney disease #Phase III trial

Global trial to test combination for chronic kidney disease

A new multinational clinical trial will investigate whether a novel treatment can help slow the progression of chronic kidney disease (CKD). The EASi-KIDNEY trial will evaluate whether vicadrostat, also known as BI 690517, improves clinical outcomes when it is given in combination with existing treatments. Read More

#News

Kidneys
#AstraZeneca #Clinical trials #Kidney disease #Precision medicine #RNA

AstraZeneca comment on precision medicine for kidney disease 

Regina Fritsche Danielson, Senior Vice President and Global Head, Research and Early Development, CVRM, AstraZeneca, shares insight with DDW’s Megan Thomas on the first precision medicine to treat APOL1-mediated kidney disease (AKMD). MT: Can you provide an overview of the key findings from the study on APOL1-mediated kidney… Read More

#Exclusive Content

Scotland
#AstraZeneca #Kidney disease #NHS Scotland #Partnership #Scotland #University of Dundee #University of Glasgow

Scottish partnership to boost kidney disease research

A new partnership between NHS Scotland, AstraZeneca and the Universities of Dundee and Glasgow hopes to accelerate research into treating chronic kidney disease. The partners will work together on new medicines to slow the progression of chronic kidney disease, reducing the risk that patients might need… Read More

#News

Dialysis machine
#Akebia #Chronic kidney disease (CKD) #FDA #Kidney disease

FDA approves new treatment option for anaemia due to kidney disease

The US Food and Drug Administration (FDA) has approved Vafseo (vadadustat) Tablets for the treatment of anaemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. Vafseo is a once-daily oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor… Read More

#News #Regulatory

Kidneys
#Chronic kidney disease (CKD) #Kidney disease #Rare disease #UK Kidney Association #University College London

Focus on rare disease treatments to beat kidney failure, says study

Focusing on rare conditions could significantly reduce the burden of kidney disease, according to a new study led by University College London (UCL) and the UK Kidney Association. The study, published in The Lancet to mark World Kidney Day on 14 March, draws on the largest… Read More

#News

Kidney on a chip technology
#Kidney disease #Organ-on-a-chip #Organoids #Preclinical investigations #University of Washington

Kidney platforms could reduce animal testing in tox studies

Kidney disease researchers at the University of Washington will use a multimillion-dollar federal grant to advance drug development platforms that would reduce reliance on animal tests. The investigators, in the UW schools of Medicine and Pharmacy, received the $7.3 million award from the National Center for… Read More

#News